BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 21513571)

  • 21. Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.
    Bilici A; Selcukbiricik F; Demir N; Oven Ustaalioglu BB; Dikilitas M; Yildiz O
    Asian Pac J Cancer Prev; 2014; 15(20):8661-6. PubMed ID: 25374186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [FOLFOX regimen in the patients with locally advanced or metastatic gastric cancer].
    Yan D; Dai H
    Zhonghua Zhong Liu Za Zhi; 2009 Mar; 31(3):217-9. PubMed ID: 19615264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The validation of matrix metalloproteinase-9 mRNA gene expression as a predictor of outcome in patients with metastatic gastric cancer.
    Al-Batran SE; Pauligk C; Wirtz R; Werner D; Steinmetz K; Homann N; Schmalenberg H; Hofheinz RD; Hartmann JT; Atmaca A; Altmannsberger HM; Jäger E
    Ann Oncol; 2012 Jul; 23(7):1699-705. PubMed ID: 22112973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Efficacy and safety evaluation of docetaxel plus oxaliplatin and capecitabine in the treatment of advanced gastric adenocarcinoma: a single center non-controlled phase II clinical trial].
    Liu Y; Ma T; Ye ZB; Zhang J; Zhu ZG
    Zhonghua Wei Chang Wai Ke Za Zhi; 2010 Mar; 13(3):177-80. PubMed ID: 20336533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer: Preliminary results of a phase II study.
    Roviello G; Petrioli R; Nardone V; Rosellini P; Multari AG; Conca R; Aieta M
    Medicine (Baltimore); 2018 May; 97(20):e10745. PubMed ID: 29768350
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma.
    Brell JM; Krishnamurthi SS; Javle M; Saltzman J; Wollner I; Pelley R; Dowlati A; Kantharaj BN; Schluchter MD; Rath L; Ivy SP; Remick SC
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):851-7. PubMed ID: 18670776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China.
    Zhu Y; Sun Y; Hu S; Jiang Y; Yue J; Xue X; Yang L; Xue L
    BMC Gastroenterol; 2017 Mar; 17(1):41. PubMed ID: 28292272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Docetaxel and Cisplatin Plus Fluorouracil compared with Modified Docetaxel, Cisplatin, and 5-Fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution.
    Inal A; Kaplan MA; Kucukoner M; Isikdogan A
    Neoplasma; 2012; 59(2):233-6. PubMed ID: 22248282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer.
    Lorenzen S; Pauligk C; Homann N; Schmalenberg H; Jäger E; Al-Batran SE
    Br J Cancer; 2013 Feb; 108(3):519-26. PubMed ID: 23322206
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer.
    Barone C; Basso M; Schinzari G; Pozzo C; Trigila N; D'Argento E; Quirino M; Astone A; Cassano A
    Gastric Cancer; 2007; 10(2):104-11. PubMed ID: 17577620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma.
    Guo JF; Zhang B; Wu F; Wang B; Xing H; Zhu GY; Nie XY; Peng J
    Chin J Cancer; 2010 Mar; 29(3):321-4. PubMed ID: 20193118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma.
    Lim JY; Cho JY; Oh KJ; Choi SH; Lee SI; Jeung HC
    Chemotherapy; 2009; 55(4):200-6. PubMed ID: 19451710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of serum levels of vascular endothelial growth factor and insulin-like growth factor-1 in advanced gastric cancer patients treated with FOLFOX chemotherapy.
    Oh SY; Kwon HC; Kim SH; Lee S; Lee JH; Graves CA; Camphausen K; Kim HJ
    Chemotherapy; 2012; 58(6):426-34. PubMed ID: 23295255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer].
    Zhao WY; Chen DY; Qi Q
    Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):295-8. PubMed ID: 21575503
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma.
    Bayraktar UD; Bayraktar S; Hosein P; Chen E; Koniaris LG; Rocha-Lima CM; Montero AJ
    Med Oncol; 2012 Sep; 29(3):1707-10. PubMed ID: 22033912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Docetaxel/Oxaliplatin/Capecitabine (TEX) triplet followed by continuation monotherapy in advanced gastric cancer.
    Ostwal V; Bose S; Sirohi B; Poladia B; Sahu A; Bhargava P; Doshi V; Dusane R; Nashikkar C; Shrikhande SV; Ramaswamy A
    Indian J Cancer; 2018; 55(1):88-93. PubMed ID: 30147101
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma.
    Ozdemir NY; Abali H; Oksüzoğlu B; Budakoglu B; Uncu D; Güler T; Odabaşi H; Zengin N
    Med Oncol; 2010 Sep; 27(3):680-4. PubMed ID: 19633962
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.
    Glatz T; Bronsert P; Schäfer M; Kulemann B; Marjanovic G; Sick O; Hopt UT; Zirlik K; Makowiec F; Hoeppner J
    Eur J Surg Oncol; 2015 Oct; 41(10):1300-7. PubMed ID: 26253194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A clinical study of paclitaxel combined with FOLFOX4 regimen as neoadjuvant chemotherapy for advanced gastric cancer].
    Qu JJ; Shi YR; Liu FR; Ma SQ; Ma FY
    Zhonghua Wei Chang Wai Ke Za Zhi; 2010 Sep; 13(9):664-7. PubMed ID: 20878572
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study.
    Richards D; Kocs DM; Spira AI; David McCollum A; Diab S; Hecker LI; Cohn A; Zhan F; Asmar L
    Eur J Cancer; 2013 Sep; 49(13):2823-31. PubMed ID: 23747051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.